Our in vitro results advise that EAM-2201 should be examined when it comes to prospective in vivo pharmacokinetic drug–drug interactions due to time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 functions and aggressive inhibition of UGT1A3 exercise. Dose-reaction effects of subcutaneously administered AM-2201 on human body temperatures and catalepsy scores https://jaschaw737iym1.ssnblog.com/profile